期刊文献+

高效液相色谱法测定癫痫患儿血清中左乙拉西坦的浓度 被引量:5

Determination of serum concentration of levetiracetam in children with epilepsy by HPLC
原文传递
导出
摘要 目的建立测定癫痫患儿血清中左乙拉西坦药物浓度的高效液相色谱(HPLC)法。方法用乙酸乙酯从血清中按液液萃取法提取左乙拉西坦和内标α-溴苯乙酮,经氮气恒流吹干富集浓缩,流动相复溶后20μL进样,0.4%磷酸-乙腈(92:8,V/V)为流动相,流速:1.0 mL·min^(-1),柱温35℃,以RP-C_(18)色谱分析柱(150 mm×3.9 mm,5μm)在210 nm波长处测定,记录左乙拉西坦与内标的峰面积比值并拟合浓度工作曲线。结果左乙拉西坦和内标峰面积比与左乙拉西坦浓度在0.234.~60.00 mg·L^(-1)的范围内线性关系良好,Y=0.065 14 X-0.004 7,r=0.999 5,最低定量限为0.234 mg·L^(-1)(S/N=4.8)。方法平均绝对回收率为(89.18±3.57)%,日间和日内RSD分别为(5.84±2.15)%和(5.48±2.61)%,冻融稳定性RSD<5%。该方法能完全分离临床可能合并所用药物的干扰(分离度R均大于1.5),采用单盲法对方法学质量控制结果RSD<4%。结论该方法经方法学验证符合血清样品的测定要求,可用于临床血药浓度测定和药动学研究。 AIM To establish (LEV) in children with epilepsy by a method for the determination of serum concentration of levetiracetam performance liquid chromatography (HPLC). METHODS The a- phenacyl bromide (a-BT) was used as internal standard (IS). LEV and IS were extracted with ethyl acetate from serum, and dried with N2 gas, then dissolved with mobile phase and 20 μL sample was injected into HPLC. The mobile phase was a mixture of 0.4% phosphate buffer and acetonitrile (92 : 8, V/V) at an isocratic flow rate of 1.0 mL-min-1. The HPLC analysis was carried out on a Xterra RP-C18 column (150 mm ×3.9 mm, 5 μm) with UV detection at 210 nm and column temperature at 35 ℃. LEV and IS peak area ratios were calculated, then standard curves were constructed using simple linear regression. RESULTS Calibration curves showed a linear and reproducible correlation between LEV serum concentrations and matched analyte to IS peak area ratios at the concentration range of 0.234 - 60.00μg.L^-1. The equation of the regression line was Y = 0.065 14 X -0.004 7 and r = 0.999 5. The minimum quantitation limit was 0.234 μg.L^-1 (S/N = 4.8) and the absolute recovery was (89.18± 3.57) %. The relative standard deviation (RSD) of inter and intra-day precision were (5.84 ±2.15) % and (5.48 ±2.61) % respectively, and freeze-thawing stability was 〈 5%. It could separate drugs combination and the interference from those drugs completely (resolving power R 〉 1.5). RSD of quality control (use single blind method) was 〈 4%. CONCLUSION This method meets the requirements for the determination of serum sample, and is suitable for the determination of LEV.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2011年第6期476-480,共5页 Chinese Journal of New Drugs and Clinical Remedies
基金 重庆市卫生局资助项目(2009-2-254)
关键词 左乙拉西坦 色谱法 高压液相 血药浓度 levetiracetam chromatography, high pressure liquid plasma concentration
  • 相关文献

参考文献8

  • 1PATSALOS PN, BERRY DJ, BOURGEOIS BF, et al. Anti- epileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2008, 49(7): 1239-1276.
  • 2CONTIN M, MOHAMED S, ALBANI F, et al. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2008, 873(1): 129-132.
  • 3LANCELIN F, FRANCHON E,KRAOUI L, et al. Therapeutic drug moni-toring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy[J]. Ther Drug Monit, 2007. 29(5)_. 576-583.
  • 4RATNARAJ N, DOHENY HC, PATSALOS PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography[J]. Ther Drug Monit, 1996, 18(2) : 154-157.
  • 5GUO T, OSWALD LM, MENDU DR, et al. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry [J]. Clin Chim Acta, 2007, 375(1-2): 115-118.
  • 6马涛,钱江华,祝晓光,童旭辉,高署,蒋志文.左乙拉西坦片健康人体药动学[J].中国医院药学杂志,2007,27(7):858-861. 被引量:5
  • 7李发美.医药高效液相色谱技术[M].北京:人民卫生出版社,2000.8.
  • 8王颖慧,魏敏吉,王云秀,王丽.高效液相色谱法测定左乙拉西坦血药浓度[J].儿科药学杂志,2010,16(4):34-36. 被引量:16

二级参考文献16

  • 1Juenke J,Brown PI,Urry FM,et al.Drug monitoring and toxicology:a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV[J].J Anal Toxicol,2006,30(1):27-30.
  • 2Lancelin F,Franchon E,Kraoul L,et al.Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection:preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy[J].Ther Drug Monit,2007,29(5):576-83.
  • 3Contin M,Mohamed S,Albani F,et al.Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy[J].J Chromatogr B Analyt Technol Biomed Life Sci,2008,15,873(1):129-32.
  • 4H Stefan,TJ Feuerstein.Novel anticonvulsant drugs[J].Pharmacology & Therapeutics,2007,113:165-183.
  • 5PN Patsalos,DJ Berry,BFD Bourgeois,et al.Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring:A position paper by the subcommission on therapeutic drug monitoring,ILAE Commission on Therapeutic Strategies[J].Epilepsia,2008,9:1-38.
  • 6Hwang H,Kim KJ.New antiepileptic drugs in pediatric epilepsy[J].Brain Dev,2008,9(30):549-555.
  • 7Emily M, N, Kiranpal S, Sangha. Levetiracetam [J]. Am J Heahh-Syst Pharm, 2001,58 : 1195-1199.
  • 8Shihabi ZK, Oles K, Hinsdale M. Analysis of the antiepileptic drug keppra by capillary electrophoresis [J] . J Chromatogr A, 2003,1004(1-2) :9-12.
  • 9Ivanova M, Piunti A, Marziali E, et al. Microemulsion elec trokinetic chromatography applied for separation of levetiracetam from other antiepileptic drugs in polypharmaey [J] . Electrophoresis, 2003,24(6) : 992-998.
  • 10Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedicalion on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials [J] . Epilepsy Res, 2003,53(1-2):47-56.

共引文献31

同被引文献50

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部